Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160790 | 0.96 | ITGB1 (0.50) | ITGB1ITGA4S1PR1S1PR3MEN1 | |
| SCHEMBL5161508 | 0.94 | ITGB1 (0.45) | ITGB1ITGA4MEN1KMT2AMAOB | |
| SCHEMBL5163398 | 0.88 | ITGB1 (0.44) | ITGB1ITGA4S1PR1S1PR3MEN1 | |
| SCHEMBL5160549 | 0.87 | FFAR2 (0.35) | ITGB1ITGA4TP53THRB | |
| SCHEMBL5158473 | 0.86 | ITGB1 (0.42) | ITGB1ITGA4S1PR1S1PR3MEN1 | |
| SCHEMBL5158322 | 0.85 | ITGB1 (0.49) | ITGB1ITGA4S1PR1S1PR3TP53 | |
| SCHEMBL5160838 | 0.85 | ITGB1 (0.49) | ITGB1ITGA4S1PR1S1PR3MAOB | |
| SCHEMBL5160727 | 0.84 | ITGB1 (0.44) | ITGB1ITGA4MEN1KMT2AMAOB | |
| SCHEMBL5407542 | 0.83 | ITGA4 (0.36) | ITGB1ITGA4MAOBTP53THRB | |
| SCHEMBL5160616 | 0.83 | ITGB1 (0.36) | ITGB1ITGA4TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGB1 9/4885ITGA4 3/4885S1PR1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.